The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.
April 17th 2024
This analysis looked at the potential connection between SARS-CoV-2 test positivity and new asthma diagnoses.
Severe Asthma Exacerbations: Spotlighting Trends Before and After COVID-19 Restrictions
The study’s investigators suggest the results in this patient population may indicate rises in clinically diagnosed viral infections from viruses other than SARS-CoV-2 following pandemic lockdown changes.
Prevalence of Anxiety, Depression Assessed for Pediatric High-Risk Asthma Patients
This new data indicates both the high mental health burden on this patient population as well as the usefulness of integrated behavioral health care teams in clinics with a pediatric specialty.
Tezepelumab Helps to Stabilize Bronchial Epithelial Immune Response to Respiratory Viruses
Though primarily observational, this research’s biggest asset is its experimental design and its exploration of viral stimulus-induced bronchial epithelial cell responses from asthmatic donors being treated with tezepelumab.
Prediction Model Effective for Community-Acquired Pneumonia in Those with Acute Asthma Exacerbations
This newly-developed prediction model evaluating CAP risk was noted as having demonstrated accuracy, strong discriminatory qualities, and practicability in clinical settings.
How Did Canadian Wildfires Impact Emergency Department Visits for Asthma Syndrome in New York?
New research on the effects of the Canadian wildfires on asthma syndrome in patients sheds light on the downstream effects of ecological disaster on regions outside of those affected.
JP Llanos Ackert, MD, C Ambrose, MD: New Data Support Tezepelumab for Asthma
May 31st 2023Investigators Dr. Jean-Pierre Llanos Ackert and Dr. Chris Ambrose share insight on the efficacy of tezepelumab in severe, uncontrolled asthma, and baseline predictors of enhanced response which support tezepelumab as a promising biologic treatment option.